A clinical trial on Postmastectomy Radiotherapy for breast cancer patients

Assessment of acute toxicities and early local recurrences in Post mastectomy breast cancer patients by Accelerated Hypo Fractionated Radiotherapy, a single arm clinical trial.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009197

Enrollment

Registered

2017-08-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients undergoing Radiation therapy for breast cancer

Interventions

Intervention1: Hypofractionated Radiotherapy of 42.5 Gy in 16 fractionations: Patients breast cancer who have underwent mastectomy will be recieving a total dose of 42.5 Gy in 16 divided fractions at

Eligibility

Inclusion criteria

Inclusion criteria: Biopsy proven patients of carcinoma breast who have underwent Modified Radical Mastectomy.

Exclusion criteria

Exclusion criteria: Patient with ischemic heart disease or other cardiac ailments. Previous history or irradiation to chest wall. Presence of metastasis to liver, brain, contralateral breast, contralateral lymph nodes, bones. Patients who have underwent Breast Conservation Surgery. ECOG performance status > 3

Design outcomes

Primary

Measure	Time frame
the incidence of grade II and above acute radiation induced dermatitisTimepoint: from the start of radiation until 3 months post treatment	—

Secondary

Measure	Time frame
incidence of other radiation induced toxicities local recurrence of the tumor Timepoint: from the start of radiation until 1 year post treatment	—

Countries

India

Contacts

Public ContactDr Niranjan V

JIPMER

vijayaraghavan.niranjan@gmail.com9840212349

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026